studies

metastatic/advanced - colorectal cancer (mCRC), atezolizumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMblaze-370 (A ; all population), 2019 1.00 [0.73; 1.37] 1.00[0.73; 1.37]IMblaze-370 (A ; all population), 201910%180NAnot evaluable progression or deaths (PFS)detailed resultsIMblaze-370 (A ; all population), 2019 1.39 [1.00; 1.94] 1.39[1.00; 1.94]IMblaze-370 (A ; all population), 201910%180NAnot evaluable objective responses (ORR)detailed resultsIMblaze-370 (A ; all population), 2019 1.00 [0.14; 7.26] 1.00[0.14; 7.26]IMblaze-370 (A ; all population), 201910%180NAnot evaluable AE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.62 [0.18; 2.22] 0.62[0.18; 2.22]IMblaze-370 (A ; all population), 201910%170NAnot evaluable AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.33 [0.18; 0.63] 0.33[0.18; 0.63]IMblaze-370 (A ; all population), 201910%170NAnot evaluable AE leading to death (grade 5)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] 0.22[0.01; 4.90]IMblaze-370 (A ; all population), 201910%170NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.49 [0.14; 1.72] 0.49[0.14; 1.72]IMblaze-370 (A ; all population), 201910%170NAnot evaluable SAE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.69 [0.32; 1.48] 0.69[0.32; 1.48]IMblaze-370 (A ; all population), 201910%170NAnot evaluable STRAE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.67 [0.24; 1.88] 0.67[0.24; 1.88]IMblaze-370 (A ; all population), 201910%170NAnot evaluable TRAE (any grade)detailed resultsIMblaze-370 (A ; all population), 2019 0.05 [0.01; 0.16] 0.05[0.01; 0.16]IMblaze-370 (A ; all population), 201910%170NAnot evaluable TRAE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.12 [0.05; 0.26] 0.12[0.05; 0.26]IMblaze-370 (A ; all population), 201910%170NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.05; 14.43] 0.89[0.05; 14.43]IMblaze-370 (A ; all population), 201910%170NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 3.61 [0.16; 81.33] 3.61[0.16; 81.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.19 [0.26; 5.50] 1.19[0.26; 5.50]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] 0.22[0.01; 4.90]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.80 [0.16; 20.18] 1.80[0.16; 20.18]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 5.48 [0.27; 111.16] 5.48[0.27; 111.16]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98] 1.79[0.06; 53.98]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Cough AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] 0.22[0.01; 4.90]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Dermatitis acneiform AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.17 [0.02; 1.47] 0.17[0.02; 1.47]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Dysphonia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.61 [0.19; 2.02] 0.61[0.19; 2.02]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Guillain-Barré syndrome AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Headache AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.24 [0.06; 0.91] 0.24[0.06; 0.91]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Intestinal perforation AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.04 [0.00; 0.77] 0.04[0.00; 0.77]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 1.79 [0.06; 53.98] 1.79[0.06; 53.98]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Rash AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.04; 4.93] 0.44[0.04; 4.93]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.44 [0.01; 13.33] 0.44[0.01; 13.33]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.22 [0.01; 4.90] 0.22[0.01; 4.90]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMblaze-370 (A ; all population), 2019 0.89 [0.02; 45.29] 0.89[0.02; 45.29]IMblaze-370 (A ; all population), 201910%170NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-20 18:31 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 183,137,138 - treatments: 361

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons